Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 11/20 | 0.40 |
| ▸ | CTSS | P25774 | 8/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8605385 | 1.00 | CA1 (0.42) | CA1CA2CA7MEN1GAA | |
| SCHEMBL2958183 | 0.86 | CA1 (0.48) | CA1CA2CA7MEN1GAA | |
| SCHEMBL17256626 | 0.85 | CA1 (0.44) | CA1CA2CA7MEN1GAA | |
| SCHEMBL28332424 | 0.85 | CA1 (0.44) | CA1CA2CA7MEN1GAA | |
| SCHEMBL7271477 | 0.84 | CA1 (0.41) | CA1CA2CA7MEN1GAA | |
| SCHEMBL25448807 | 0.81 | CA1 (0.44) | CA1CA2CA7MEN1GAA | |
| SCHEMBL8277871 | 0.81 | CA1 (0.39) | CA1CA2CA7MEN1GAA | |
| SCHEMBL10066466 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL20901248 | 0.80 | MAPT (0.36) | CA1CA2CA7MEN1GAA | |
| SCHEMBL15329419 | 0.79 | CA1 (0.43) | CA1CA2CA7MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590541-B1 | DRUG-CONJUGATES AND USES THEREOF | CONCORTIS BIOSYSTEMS CORP (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20110182850-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| US-20110178107-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182850-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CA1 2516/4885CA2 1716/4885CA7 683/4885 |
| US-20110178107-A1 | HCV PROTEASE INHIBITORS | HAVCR2, RNASE1, SERPINB1 | CA1 3996/4885CA2 4435/4885CA7 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.